Gender‐affirming hormone therapy and the risk of sex hormone‐dependent tumours in transgender individuals—A systematic review

@article{McFarlane2018GenderaffirmingHT,
  title={Gender‐affirming hormone therapy and the risk of sex hormone‐dependent tumours in transgender individuals—A systematic review},
  author={Thomas McFarlane and J. Zajac and A. Cheung},
  journal={Clinical Endocrinology},
  year={2018},
  volume={89},
  pages={700 - 711}
}
Cancers are a leading cause of death worldwide, and transgender individuals are no exception. The effects of gender‐affirming hormone therapy (GAHT) on sex hormone‐dependent tumours are unclear. Therefore, this review seeks to determine whether tumour risk in transgender individuals differs from the general population, to guide clinical screening recommendations. 
Health considerations for transgender women and remaining unknowns: a narrative review
Approach to Interpreting Common Laboratory Pathology Tests in Transgender Individuals
Cancer screening in the transgender population: a review of current guidelines, best practices, and a proposed care model.
Gender affirming medical care of transgender youth.
...
1
2
...

References

SHOWING 1-10 OF 75 REFERENCES
Triple negative breast cancer in a male‐to‐female transsexual
Metastatic prostate cancer in transsexual diagnosed after three decades of estrogen therapy.
...
1
2
3
4
5
...